NCT05184868View on ClinicalTrials.gov

AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 3, 2022

Primary Completion Date

September 9, 2022

Study Completion Date

September 9, 2022

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

AT247

Ultra rapid acting prandial insulin aspart

DRUG

NovoLog

Rapid acting prandial insulin aspart

DRUG

Fiasp

Fast acting prandial insulin aspart

Trial Locations (1)

91911

ProSciento, Inc, Chula Vista

All Listed Sponsors
lead

Arecor Limited

INDUSTRY

NCT05184868 - AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study | Biotech Hunter | Biotech Hunter